Kestra expects $137M FY2027 revenue while targeting 70%+ gross margins in the next few years (NASDAQ:KMTS)
Kestra Medical (KMTS) Q4 FY2026 earnings call recap: 66% revenue growth, margin expansion, $137M FY2027 outlook, WCD share gains & financingâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Kestra Medical (KMTS) Q4 FY2026 earnings call recap: 66% revenue growth, margin expansion, $137M FY2027 outlook, WCD share gains & financingâread now.
Kestra expects $137M FY2027 revenue while targeting 70%+ gross margins in the next few years (NASDAQ:KMTS) | Seeking Alpha
Save
Play
(
9min
)
Comments
Earnings Call Insights: Kestra Medical Technologies (KMTS) Q4 fiscal 2026
Management View
"We concluded fiscal 2026 with another strong quarter" and "Revenue was $28.6 million" alongside "over 6,300 prescriptions written for the ASSURE system," Brian Webster said (Founder, President, CEO & Director Brian Webster).
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
What is Kestra Medical Technologies' revenue and growth outlook for FY2027?
Kestra projects $137 million in revenue for FY2027, reflecting 44% year-over-year growth, driven by increased account penetration, territory expansion, and in-network patient mix improvements.
How is Kestra Medical Technologies' gross margin expected to trend in coming years?
Gross margin reached 54.8% in Q4 and management expects it to trend upward, with a projected 700 basis point increase in FY2027 and long-term potential over 70% as commercial scaling continues.
What financial and operational investments is Kestra Medical Technologies making to support growth?
Kestra is growing its salesforce, expanding sales territories, advancing product deployment, increasing prescribers and facilities, improving revenue cycle, and has secured a $200 million term loan for flexibility and potential tuck-in M&A deals.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.
Sidus Fortis VPX Commercial Launch in 2027 Backed by $158.5M Funding
Sidus Space announces the commercial availability of its Fortis VPX edge computing module by early 2027, supported by $158.5M raised in Q2 2025. Learn about its technology advantages, market outlook, and financial health.
TOMI Reaffirms 2026 Revenue Guidance of at Least $12M, Sets $10M Funding Goal for Carbonium Core Merger
TOMI Environmental Solutions reaffirms its 2026 revenue guidance of at least $12 million and advances its merger with Carbonium Core, targeting $10 million in funding. This article analyzes the strategic implications, industry context, and potential risks.
